MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Peritoneal (Abdominal Mesothelioma)

Malignant peritoneal mesothelioma; cancer of the lining of the abdominal caviety.

MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.

Pleura and Peritoneum 2019 June 27 [Link] Sgarbura O, Gourgou S, Tosi D, Bakrin N, Bouazza N, Delaine S, De Forges H, Pocard M, Quénet F Abstract BACKGROUND: Malignant peritoneal mesothelioma (MPM) is a rare tumoral disease characterized by the diffuse involvement of the peritoneal serosa. The standard frontline treatment of MPM is cytoreductive surgery […]

Comments Off on MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.

Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.

Oncoimmunology 2019 April 17 [Link] Bertino P, Premeaux TA, Fujita T, Haun BK, Marciel MP, Hoffmann FW, Garcia A, Yiang H, Pastorino S, Carbone M, Niki T, Berestecky J, Hoffmann PR, Ndhlovu LC Abstract Galectin-9 has emerged as a promising biological target for cancer immunotherapy due to its role as a regulator of macrophage and […]

Comments Off on Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.

Meningeal metastasis of a malignant peritoneal mesothelioma: A case report and literature review.

Cancer Biology and Therapy 2019 August 14 [Link] Jiang Y, Mei Z, Cao H, Li S, Xu H, Qiu H, Liu Y Abstract Malignant peritoneal mesothelioma is a very rare tumor originating from the peritoneal serous mesothelium. Meningeal metastasis of malignant peritoneal is even more rare. Here, we reported a case of a 60-year-old female […]

Comments Off on Meningeal metastasis of a malignant peritoneal mesothelioma: A case report and literature review.

Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy.

Environmental Health 2019 August 7 [Link] Luberto F, Ferrante D, Silvestri S, Angelini A, Cuccaro F, Nannavecchia AM, Oddone E, Vicentini M, Barone-Adesi F, Cena T, Mirabelli D, Mangone L, Roncaglia F, Sala O, Menegozzo S, Pirastu R, Azzolina D, Tunesi S, Chellini E, Miligi L, Perticaroli P, Pettinari A, Bressan V, Merler E, Girardi […]

Comments Off on Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy.

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

CA 2019 July 8 [Link] Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS10, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang< H, Zauderer MG, Pass HI/strong> Abstract Mesothelioma affects mostly […]

Comments Off on Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.

Japanese Journal of Clinical Oncology 2019 July 9 [Link] Nagata Y, Sawada R, Takashima A, Shoji H, Honma Y, Iwasa S, Amano K, Kato K, Hamaguchi T, Shimada Y, Saruta M, Boku N Abstract BACKGROUND: Malignant peritoneal mesothelioma (MPeM) is a rare cancer for which no standard systemic chemotherapy has been established. While cisplatin plus […]

Comments Off on Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.

Diagnostic Value of BAP1, GLUT-1 and Desmin Expression in the Discrimination Between Reactive Mesothelial Proliferation and Malignant Mesothelioma in Tissues and Effusions.

Cytopathology 2019 June 5 [Link] Önder S, Özogul E, Koksal D, Sarinc Ulasli S, Firat P, Emri S Abstract OBJECTIVE: The aim of this study was to investigate the utility of BAP1, GLUT-1 and desmin expression by immunohistochemistry in the discrimination between reactive and malignant mesothelial proliferations. METHODS: A total of 88 biopsies and 30 […]

Comments Off on Diagnostic Value of BAP1, GLUT-1 and Desmin Expression in the Discrimination Between Reactive Mesothelial Proliferation and Malignant Mesothelioma in Tissues and Effusions.

Signet ring cell mesothelioma; A diagnostic challenge

Pathology Research and Practice 2019 May 22 [Link] Wang H, Herath C Abstract Signet ring cell mesothelioma is a rare variant of epithelioid mesothelioma with limited cases published. It has a male predilection and most commonly occurs on pleura; it can also arise in the peritoneal cavity. The signet ring cell morphology can pose a […]

Comments Off on Signet ring cell mesothelioma; A diagnostic challenge

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.

BMJ Open 2019 May 14 [Link] de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts JGJV, Madsen EVE Abstract INTRODUCTION: Malignant peritoneal mesothelioma (MPM) is an uncommon but aggressive neoplasm and has a strong association with asbestos exposure. MPM has low survival rates of approximately 1 year even after (palliative) surgery and/or systemic chemotherapy. […]

Comments Off on Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.

Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma.

Annals of Surgical Oncology 2019 May 8 [Link] Ali YM, Sweeney J, Shen P, Votanopoulos K, McQuellon R, Duckworth K, Perry KC, Russell G, Levine EA Abstract INTRODUCTION: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is an accepted treatment for peritoneal mesothelioma. In this study, we evaluated QOL after HIPEC for peritoneal mesothelioma. METHODS: This […]

Comments Off on Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma.